Related Experiment Video
Updated: Aug 15, 2026
10:58
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Progress in Protein Nanoparticle Vaccines for Human Viral Diseases
Yang He1, Junshi Wang2, Jinxiu Li3
1The First School of Clinical Medicine, Zunyi Medical University, West No. 6 Xuefu Road, Xinpu District, Zunyi, Guizhou 563006, People's Republic of China.
ACS Omega
|August 14, 2026
Summary
Protein nanoparticle vaccines offer a promising strategy to overcome challenges in antiviral vaccine development, enhancing immunogenicity and cross-protection against evolving viruses.
Area of Science:
- Vaccinology
- Structural Biology
- Immunology
Background:
- Developing effective antiviral vaccines against rapidly evolving viruses is challenging due to insufficient immunogenicity and limited cross-protection.
- Protein nanoparticle vaccine platforms present a promising strategy, offering multivalent antigen presentation, structural stability, and enhanced immunogenicity.
Purpose of the Study:
- To review recent advances in protein nanoparticle vaccines for major human viral diseases.
- To emphasize how nanoparticle characteristics influence immunogenicity and broad-spectrum immune responses.
- To discuss progress in mosaic antigen display, germline-targeting immunogens, and clinical translation.
Main Methods:
- Review of scientific literature on protein nanoparticle vaccine platforms.
- Analysis of various protein nanoparticle scaffolds (e.g., ferritin, lumazine synthase, E2p, I53-50, I301, mi3).
- Examination of antigen-display strategies and their impact on immune responses.
Main Results:
- Protein nanoparticles enhance immunogenicity and stability for viral antigen presentation.
- Nanoparticle geometry, assembly, and antigen display significantly influence immune responses.
- Progress has been made in mosaic antigen display and germline-targeting strategies.
Conclusions:
- Protein nanoparticle platforms are versatile for structure-guided antiviral vaccine development.
- Continued scaffold engineering and vaccine design are crucial for future progress.
- These platforms hold potential for improved broad-spectrum antiviral immunity.
